BCAB BioAtla Inc

Price (delayed)

$3.59

Market cap

$5.95M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$41.22

Enterprise value

$10.08M

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 29

BioAtla® is a San Diego biotech company that develops novel monoclonal antibody and cell based therapeutics using our proprietary Conditionally Active Biologics™ (CAB) and Comprehensive Integrated Antibody Optimization (CIAO!™) platforms. ...

Highlights
The company's EPS rose by 33% YoY and by 18% QoQ
BioAtla's net income has increased by 18% YoY and by 15% QoQ
BioAtla's quick ratio has shrunk by 96% YoY and by 72% QoQ
The company's gross profit has shrunk by 82% YoY

Key stats

What are the main financial stats of BCAB

BCAB stock price

How has the BioAtla stock price performed over time
Intraday
5.59%
1 week
-11.36%
1 month
-23.62%
1 year
-84.87%
YTD
-87.35%
QTD
-55.4%

Financial performance

How have BioAtla's revenue and profit performed over time
Revenue
$2M
Gross profit
$2M
Operating income
-$51M
Net income
-$50.62M
Gross margin
100%
Net margin
-2,530.9%
The company's gross profit has shrunk by 82% YoY
The revenue has dropped by 82% year-on-year
BCAB's operating income is up by 24% YoY and by 14% from the previous quarter
BioAtla's net income has increased by 18% YoY and by 15% QoQ

Price vs fundamentals

How does BCAB's price correlate with its fundamentals

Growth

What is BioAtla's growth rate over time

Valuation

What is BioAtla stock price valuation
P/E
N/A
P/B
N/A
P/S
2.7
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.04
The company's EPS rose by 33% YoY and by 18% QoQ
The equity has declined by 3.1% since the previous quarter
The revenue has dropped by 82% year-on-year

Efficiency

How efficient is BioAtla business performance
BioAtla's ROA has plunged by 177% YoY and by 23% from the previous quarter
The company's return on sales rose by 15% QoQ

Dividends

What is BCAB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BCAB.

Financial health

How did BioAtla financials performed over time
The company's total assets is 81% lower than its total liabilities
BioAtla's quick ratio has shrunk by 96% YoY and by 72% QoQ
The current ratio has plunged by 94% YoY and by 59% from the previous quarter
BCAB's debt is 116% higher than its equity
BioAtla's debt to equity has shrunk by 116% YoY but it has increased by 6% QoQ
The equity has declined by 3.1% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.